Independent Advisor Alliance Has $363,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Independent Advisor Alliance grew its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 29.2% in the 3rd quarter, Holdings Channel reports. The fund owned 7,719 shares of the company’s stock after buying an additional 1,745 shares during the period. Independent Advisor Alliance’s holdings in CRISPR Therapeutics were worth $363,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Global Trust Asset Management LLC increased its position in CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC increased its holdings in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in CRISPR Therapeutics in the second quarter valued at about $35,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics during the third quarter valued at about $43,000. Institutional investors own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

CRSP has been the subject of several recent research reports. Truist Financial lowered their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Rodman & Renshaw initiated coverage on CRISPR Therapeutics in a research report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price target on the stock. Finally, Stifel Nicolaus cut their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $74.94.

CRISPR Therapeutics Trading Up 3.1 %

Shares of CRISPR Therapeutics stock opened at $50.84 on Friday. CRISPR Therapeutics AG has a 12-month low of $43.42 and a 12-month high of $91.10. The company has a market capitalization of $4.34 billion, a P/E ratio of -17.96 and a beta of 1.67. The stock has a fifty day simple moving average of $48.07 and a 200 day simple moving average of $51.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the previous year, the company earned ($1.41) earnings per share. On average, analysts predict that CRISPR Therapeutics AG will post -5.2 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,382 shares of company stock worth $1,917,679 in the last 90 days. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.